Indication
Biochemical Recurrence of Prostate Cancer
5 clinical trials
5 products
Clinical trial
A Prospective, Open-Label, Single-Arm, Multi-center Study to Evaluate the Diagnostic Efficacy and Safety of 68Ga-PSMA-11 PET/CT or PET/MRI in Patients With Biochemical Recurrent Prostate CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Product
68Ga-PSMA-11Clinical trial
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate CancerStatus: Completed, Estimated PCD: 2023-08-08
Product
64Cu-SAR-bisPSMAProduct
64Cu-SAR-BBNClinical trial
64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate CancerStatus: Recruiting, Estimated PCD: 2025-07-01
Product
PembrolizumabClinical trial
A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate CancerStatus: Recruiting, Estimated PCD: 2025-07-01
Product
Copper Cu 64 PSMA I&T